Opebacan
Alternative Names: BPI 21; Neuprex; rBPI21; Recombinant bactericidal permeability increasing protein 21Latest Information Update: 24 Oct 2021
At a glance
- Originator New York University
- Developer XOMA
- Class Antibacterials; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal infections; Postoperative infections; Radiation injuries; Wound infections
- Discontinued Graft-versus-host disease; Post-traumatic infections
Most Recent Events
- 03 Aug 2010 Discontinued - Phase-I/II for Graft-versus-host disease in USA (Parenteral)
- 09 Jan 2007 Phase-I/II clinical trials in Graft-versus-host disease in USA (Parenteral)
- 06 Sep 2006 Opebacan has received orphan drug status for Meningococcal infections in the European Union